Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)

You may also be interested in...



Teva To Investigate High-Dose Copaxone

A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.

Teva To Investigate High-Dose Copaxone

A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.

Teva Foresees Sustained Growth Despite Slow Start To Fiscal 2006

Generics firm expects growth from generic Pravachol and generic Zocor exclusivity periods.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel